[go: up one dir, main page]

Ou et al., 2022 - Google Patents

Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificity

Ou et al., 2022

View PDF
Document ID
2591071682834309251
Author
Ou Y
Liu M
Zhan K
Wu W
Huang J
Sun H
Zheng H
Yu X
Gong H
Han Z
Chen A
Liao Y
Lin Y
Liu G
Liu Q
Ma R
Mei Y
Tang X
Weng Z
Wu J
Ye Y
Zhang T
Chen J
Chen L
Ding Q
Fan H
Hu J
Huang J
Huang L
Li Q
Li S
Liu M
Shi J
Tan X
Wang X
Xiang R
Yan Q
Zhang J
Zheng W
Zhong S
Publication year
Publication venue
bioRxiv

External Links

Snippet

The clinical success of T-cell receptor (TCR)-based immunotherapy depends on the efficacy and specificity of TCRs. Naturally occurring TCRs have limited anti-tumor potency due to their low affinity for tumor antigens. Affinity enhancement is a promising strategy to generate …
Continue reading at www.biorxiv.org (PDF) (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Shafer et al. Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects
JP7730765B2 (en) MAGE-A4 T-CELL RECEPTOR AND METHODS OF USE THEREOF
TWI840351B (en) T cell receptors and engineered cells expressing same
EP3177314B1 (en) T cell immunotherapy specific for wt-1
US12358968B2 (en) Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
US11730796B2 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
EP3995142A2 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
AU2018360599A1 (en) Process for generating therapeutic compositions of engineered cells
JP2023534808A (en) Receptors that provide targeted co-stimulation for adoptive cell therapy
JP2019512242A (en) Transfected T cells and T cell receptors for use in immunotherapy for cancer
US20230178239A1 (en) Methods of identifying features associated with clinical response and uses thereof
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
JP2023133505A (en) Cyclin A1-specific T cell receptor and its uses
US20230192886A1 (en) Adoptive cell therapy combination treatment and compositions thereof
EP3209679A1 (en) T cell-based immunotherapeutics
Ou et al. Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificity
EP4253410A1 (en) Ras mutant epitope peptide and t cell receptor recognizing ras mutant
US20240058447A1 (en) Use of fusion constructs for il-2 independent t cell therapy
Zhou et al. Alanine mutagenesis in the complementarity determining region 3 of the MTB and HIV-1 peptide-bispecific T cell receptor beta chain affects ligand recognition
CN121127488A (en) T cell receptor and application thereof
US20240122980A1 (en) Use of tim-3 cytoplasmic tail in chimeric antigen receptors
HK40074429A (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2024148223A1 (en) Epitope engineering of cd38 cell-surface receptors
Dow et al. 7 The Development of Adoptive T-Cell Immunotherapies for Cancer
CN120303292A (en) pMHC-binding heterodimeric receptor with improved discrimination for low-affinity and high-affinity pMHC and without binding to CD3